(Q27851395)

13 November 2016

title

XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer (English)

1 reference

PubMed

PubMed publication ID

13 November 2016

0 references

1 reference

neoadjuvant chemotherapy

1 reference

based on heuristic

inferred from title

cervix uterine cancer

1 reference

Hyun Hoon Chung

1

0 references

Mi-Kyung Kim

2

0 references

Jae Weon Kim

3

0 references

Noh-Hyun Park

4

0 references

Yong-Sang Song

5

0 references

Soon-Beom Kang

6

0 references

Hyo-Pyo Lee

Global cancer statistics, 2002

7

0 references

language of work or name

English

0 references

publication date

December 2006

0 references

published in

Gynecologic Oncology

0 references

volume

103

0 references

issue

3

0 references

page(s)

1031-7

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.016

A possible new trend in the management of the carcinoma of the cervix uteri

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.016

Estimating the world cancer burden: Globocan 2000.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.016

Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.016

A prospective surgical pathological study of stage I squamous carcinoma of the cervix: a Gynecologic Oncology Group Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.016

The uses and limitations of DNA flow cytometry in stage IB or II cervical carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.016

Neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer. Prognostic factors for response and survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.016

Comparative study of the patients with locally advanced stages I and II cervical cancer treated by radical surgery with and without preoperative adjuvant chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.016

Neoadjuvant chemotherapy with vincristine and cisplatin followed by radical hysterectomy and pelvic lymphadenectomy for FIGO stage IB bulky cervical cancer: a Gynecologic Oncology Group pilot study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.016

Results of a Prospective Randomized Trial with Neoadjuvant Chemotherapy in Stage IB, Bulky, Squamous Carcinoma of the Cervix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.016

Neoadjuvant chemotherapy with cisplatin, vincristine, and bleomycin and radical surgery in early-stage bulky cervical carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.016

Prognostic Factors in Patients with Bulky Stage IB or IIA Cervical Carcinoma Undergoing Neoadjuvant Chemotherapy and Radical Hysterectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.016

Identification of human papillomavirus types 16 and 18 deoxyribonucleic acid sequences in bulky cervical cancer after chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.016

Tumor response to neoadjuvant chemotherapy correlates with the expression of P-glycoprotein and PCNA but not GST-pi in the tumor cells of cervical carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.016

A common polymorphism in XRCC1 as a biomarker of susceptibility for chemically induced genetic damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.016

Effect of the methylenetetrahydrofolate reductase C677T polymorphism on patients with cisplatin/gemcitabine-treated stage IV non-small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.016

The prognostic significance of genetic polymorphisms (Methylenetetrahydrofolate Reductase C677T, Methionine Synthase A2756G, Thymidilate Synthase tandem repeat polymorphism) in multimodally treated oesophageal squamous cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.016

Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)--novel predictors for response and survival in gastric cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.016

Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.016

ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.016

Pharmacogenetics for individualized cancer chemotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.016

Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.016

Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.016

Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.016

XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.016

Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.016

A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.016

Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.016

DNA repair and cisplatin resistance in non-small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.016

DNA repair: a double-edged sword

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.016

Association of XRCC1 Arg399Gln and OGG1 Ser326Cys polymorphisms with the risk of cervical cancer in Japanese subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.016

Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.016

XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.016

DNA repair gene polymorphisms, bulky DNA adducts in white blood cells and bladder cancer in a case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.016

Amino acid substitution variants of APE1 and XRCC1 genes associated with ionizing radiation sensitivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.016

Alterations in the expression of transcription factors and the reduced folate carrier as a novel mechanism of antifolate resistance in human leukemia cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.016

Reduced folate carrier gene silencing in multiple antifolate-resistant tumor cell lines is due to a simultaneous loss of function of multiple transcription factors but not promoter methylation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.016

Impaired CREB-1 phosphorylation in antifolate-resistant cell lines with down-regulation of the reduced folate carrier gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.016

Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.016

New strategies for identifying gene-gene interactions in hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.016

Power of multifactor dimensionality reduction for detecting gene-gene interactions in the presence of genotyping error, missing data, phenocopy, and genetic heterogeneity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.016

Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.016

10.1016/J.YGYNO.2006.06.016

7 January 2021

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

16875718

1 reference

Consolidated OpenCitations Corpus – April 2017